GlassScriptPhysician profile
Li-Chien Chen
NPI 1528492949
$7,948.28
in general payments reported to CMS, 2019-2025
22 companies · $228 in 2025
The $228 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,275 · 2020: $895 · 2021: $2,191 · 2022: $1,452 · 2023: $984 · 2024: $922 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,005 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,004.66 |
| Education | $129.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,536.73 | 2021-2025 | Avycaz, Dalvance, Teflaro |
| Cipla USA INC. | $1,220.51 | 2021 | |
| Allergan, INC. | $902.58 | 2019-2020 | |
| Melinta Therapeutics, LLC | $785.14 | 2022-2025 | Rezzayo, Kimyrsa, Vabomere |
| Merck Sharp & Dohme LLC | $513.02 | 2019-2025 | Zerbaxa, Dificid, Delstrigo |
| Gilead Sciences, INC. | $484.86 | 2019-2021 | |
| La Jolla Pharmaceutical Company | $397.62 | 2022-2024 | Giapreza, Xacduro |
| Shionogi INC | $372.99 | 2019-2025 | Fetroja |
| Astellas Pharma US INC | $343.56 | 2020-2024 | |
| Viiv Healthcare Company | $223.26 | 2019-2021 | |
| Tetraphase Pharmaceuticals, INC. | $193.22 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $181.76 | 2023-2024 | Rebyota |
| Janssen Pharmaceuticals, INC | $117.74 | 2021 | |
| Acell, INC. | $115.85 | 2019 | |
| Paratek Pharmaceuticals, INC. | $97.28 | 2020-2024 | Nuzyra |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $95.95 | 2022 | |
| Pfizer INC. | $94.37 | 2019-2021 | |
| Smith+Nephew, INC. | $89.03 | 2023-2024 | Pico |
| Janssen Biotech, INC. | $74.31 | 2019-2021 | |
| Janssen Products, LP | $60.00 | 2021 | |
| Abiomed | $30.13 | 2023 | Impella |
| Tactile Systems Technology INC | $18.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Li-Chien Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.